

Dennis J Schaefer-Babajew

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9599457/dennis-j-schaefer-babajew-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

20
papers

2,703
citations

15
h-index

23
g-index

23
ext. papers

4,578
ext. citations

35.9
avg, IF

5.45
L-index

#	Paper	IF	Citations
20	Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose. 2022,		3
19	Increased Memory B Cell Potency and Breadth After a SARS-CoV-2 mRNA Boost.. <i>Nature</i> , 2022,	50.4	14
18	Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. <i>Nature</i> , 2021,	50.4	69
17	Evolution of Antibody Immunity to SARS-CoV-2 2021,		43
16	Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies 2021,		24
15	Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year 2021,		19
14	Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. <i>Nature</i> , 2021, 595, 426-431	50.4	247
13	Vaccine Breakthrough Infections with SARS-CoV-2 Variants. <i>New England Journal of Medicine</i> , 2021, 384, 2212-2218	59.2	347
12	Evolution of antibody immunity to SARS-CoV-2. <i>Nature</i> , 2021, 591, 639-644	50.4	652
11	Persistent cellular immunity to SARS-CoV-2 infection. <i>Journal of Experimental Medicine</i> , 2021, 218,	16.6	59
10	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. <i>Nature</i> , 2021, 592, 616-622	50.4	730
9	Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. <i>Immunity</i> , 2021, 54, 1853-1868.e7	32.3	83
8	High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. <i>Nature</i> , 2021,	50.4	65
7	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants 2021,		54
6	Persistent Cellular Immunity to SARS-CoV-2 Infection 2020,		9
5	Risk of Zika microcephaly correlates with features of maternal antibodies. <i>Journal of Experimental Medicine</i> , 2019, 216, 2302-2315	16.6	28
4	A Combination of Two Human Monoclonal Antibodies Prevents Zika Virus Escape Mutations in Non-human Primates. <i>Cell Reports</i> , 2018, 25, 1385-1394.e7	10.6	43

- 3 Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico. *Cell*, **2017**, 169, 597-609.e1199
- 2 Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination 7
- 1 High genetic barrier to escape from human polyclonal SARS-CoV-2 neutralizing antibodies 7